×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Mechanism: Neuroinflammation Across AD, PD, ALS, FTD, and HD
mechanism
3,668 words
KG: ent-dise-93f3d65f
Contents
Neuroinflammation Across AD, PD, ALS, FTD, and HD
⚙
Mechanism Info
Name
ent-dise-93f3d65f
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
SASP-Mediated Complement Cascade Amplification
Score: 0.91
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.73
Circadian-Synchronized LRP1 Pathway Activation
Score: 0.71
Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
TREM2-mediated microglial tau clearance enhancement
Score: 0.59
Microbial Inflammasome Priming Prevention
Score: 0.65
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Microglial Purinergic Reprogramming
Score: 0.70
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.56
Circadian-Synchronized Proteostasis Enhancement
Score: 0.74
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Circadian Clock-Autophagy Synchronization
Score: 0.76
Temporal Decoupling via Circadian Clock Reset
Score: 0.54
Senescent Cell Mitochondrial DNA Release
Score: 0.74
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Circadian Rhythm Entrainment of Reactive Astrocytes
Score: 0.72
Optogenetic Microglial Deactivation via Engineered Inhibitor
Score: 0.66
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
TREM2-Dependent Microglial Senescence Transition
Score: 0.95
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.84
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.79
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.78
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
Show 25 more
Related Analyses (30)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · completed
Show 25 more
Related Experiments (30)
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Microglial Contributions to Huntington's Disease Pathogenesi
validation · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Epigenetic Dysregulation in Huntington's Disease — Therapeut
validation · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice
falsification · proposed · Score: 0.40
s:** - GPR32 knockout in microglia should worsen neuroinflam
falsification · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
s:** - ALOX15 overexpression in healthy astrocytes should be
falsification · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Proposed experiment from debate on Microglia activate astroc
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
Show 25 more
See Also (15)
Endosomal-Lysosomal Pathway in Neurodegeneration
mechanism · Pages share 7 hypotheses
Retinal Degeneration Pathway in Neurodegeneration
mechanism · Pages share 7 hypotheses
Convergent Pathways in Neurodegeneration
mechanism · Pages share 7 hypotheses
Dystrophic Neurites in Neurodegeneration
mechanism · Pages share 7 hypotheses
HMGB1 Signaling in Neurodegeneration
mechanism · Pages share 7 hypotheses
Microglial Priming Pathway in Neurodegeneration
mechanism · Pages share 7 hypotheses
Antibody Therapy in Neurodegeneration
mechanism · Pages share 7 hypotheses
Axon Guidance Pathways in Neurodegeneration
mechanism · Pages share 7 hypotheses
COVID-19 Neurodegeneration Mechanism
mechanism · Pages share 7 hypotheses
Down Syndrome Neurodegeneration Pathway
mechanism · Pages share 7 hypotheses
Galectin-3 Mechanism in Neurodegeneration
mechanism · Pages share 7 hypotheses
gp130/IL-6 Family Cytokine Signaling in Neurodegenerati
mechanism · Pages share 7 hypotheses
IL-1 Signaling Pathway in Neurodegeneration
mechanism · Pages share 7 hypotheses
Lipid Metabolism Dysregulation in Neurodegeneration
mechanism · Pages share 7 hypotheses
Senescent Cell Clearance in Neurodegeneration
mechanism · Pages share 7 hypotheses
Show 10 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)